The IVADo regimen - A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: A pilot study on behalf of the European pediatric soft tissue sarcoma study group

Cancer

Volumn 103, Issue 8, 2005, Pages 1719-1724

  Bisogno, Gianni ^a   Ferrari, Andrea ^b   Bergeron, Christophe ^c   Scagnellato, Angela ^a   Prete, Arcangelo ^d   Alaggio, Rita ^e   Casanova, Michela ^b   D'Angelo, Paolo ^f   Di Cataldo, Andrea ^d   Carli, Modesto ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f Di Cristina Hospital   (Italy)

Author keywords

Children; Dose intensity; Doxorubicin; Rhabdomyosarcoma; Soft tissue sarcoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; THIOTEPA; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CLINICAL ARTICLE; CONSTIPATION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INFECTION; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROECTODERM TUMOR; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; REMISSION; RHABDOMYOSARCOMA; RISK ASSESSMENT; SEIZURE; SEPTIC SHOCK; SKIN TOXICITY; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TOXICITY; VEIN OCCLUSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; INFANT; MALE; PILOT PROJECTS; RISK FACTORS; SARCOMA; VINCRISTINE;

EID: 20144388870     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20928     Document Type: Article

References (14)

1. Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs. 2002;4:21-28.
2. Ruymann FB, Grovas AC. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest. 2000;18:223-241.
3. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61:209-220.
4. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71:1904-1922.
5. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol. 1999;17:2796-2803.
6. Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a Phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol. 2001;37:442-448.
7. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
8. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol. 2003;40:276-287.
9. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991;83:1460-1470.
10. Strauss SJ, McTiernan A, Driver D, et al. Single center experience of a new intensive induction therapy for Ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. J Clin Oncol. 2003;21:2974-2981.
11. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist. 2002;7:348-359.
12. Bisogno G, de Kraker J, Weirich A, et al. Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol. 1997;29:245-251.
13. Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol. 2004;22:1894-1901.
14. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17:3706-3719.